Product logins

Find logins to all Clarivate products below.


Alexandr Ishkin, PhD

Principal Consultant for Discovery and Translational Science Consulting

Alex has over 15 years of experience as a science analyst in systems biology and bioinformatics, working with GeneGo and later Thomson Reuters and Clarivate. His key expertise is in network and pathway analysis of high-throughput molecular data sets, such as DNA-Seq, RNA-Seq, single-cell RNA-Seq, gene expression microarray, proteomics and metabolomics, in the context of drug development.
Alex is an expert in Clarivate’s products MetaBaseTM and CDDI. For over 10 years, he has been responsible for development and maintenance of Clarivate’s metabaseR package that enables efficient access to and bioinformatics analyses of the extensive MetaBaseTM content.

Alex is a program manager and principal software developer for two Clarivate-led precompetitive consortia, CBDD and ABC. The CBDD consortium (Computational Biology for Drug Discovery) was launched in 2013. Within the consortium, Alex developed a toolkit of over 70 advanced network analysis algorithms for drug discovery. Consortium members include Novartis, Pfizer, Sanofi, Roche, Merck, Janssen, Takeda, Boehringer Ingelheim, Eli Lilly, BMS, Abbvie, Biogen, UCB, Regeneron, and Daiichi Sankyo. The ABC (Algorithm Benchmarking Consortium) program is centered around benchmarking bioinformatics tools relevant for drug development research and has been running since 2021. Since its inception, the program helped customers to identify best-performing tools and practices across many areas of bioinformatics research.


arrow_forward
Get in touch with Alexandr

Latest news

News July 29, 2026
Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise ​LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…

News July 29, 2026
Clarivate Reports Second Quarter 2026 Results

— Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile with previously announced Life Sciences & Healthcare segment divestiture…

News July 20, 2026
Clarivate RiskMark Wins 2026 CODiE Award for Best AI Tool for Lawyers

Prestigious awards program recognizes innovative AI technology transforming trademark risk assessment for legal professionals London, U.K. July, 20, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.